EVAX (Evaxion AS) ROC (Joel Greenblatt) %: -423.00% (As of Mar. 2026)


EVAX Evaxion AS EVAX
29 GF Score
Price $3.43
! 2 Warning Signs
View Full Analysis

What is Evaxion AS ROC (Joel Greenblatt) %?

Evaxion AS EVAX +5.25% 29 ROC (Joel Greenblatt) % is -423.00% as of Mar. 2026. GuruFocus rates EVAX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,321 Biotechnology companies, Evaxion AS ranks worse than 50.95% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Evaxion AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -423.00%.

The historical rank and industry rank for Evaxion AS's ROC (Joel Greenblatt) % or its related term are showing as below:

EVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10277.02   Med: -699.23   Max: -226.42
Current: -311.82

During the past 9 years, Evaxion AS's highest ROC (Joel Greenblatt) % was -226.42%. The lowest was -10277.02%. And the median was -699.23%.

EVAX's ROC (Joel Greenblatt) % is ranked worse than
50.95% of 1321 companies
in the Biotechnology industry
Industry Median: -296.6 vs EVAX: -311.82

Evaxion AS's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 47.80% per year.


Evaxion AS  (NAS:EVAX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Evaxion AS ROC (Joel Greenblatt) % Related Terms


Evaxion AS ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Evaxion AS's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS ROC (Joel Greenblatt) % Chart

Evaxion AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -910.14 -469.96 -488.31 -264.55 -226.42

Evaxion AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -156.52 -528.29 630.64 -997.59 -423.00

EVAX vs SER, NRSN, IGC: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Evaxion AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion AS ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion AS's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Evaxion AS's ROC (Joel Greenblatt) % falls into.


EVAX
29GF Score
Evaxion AS EVAX
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evaxion AS ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.616) - (2.186 + 0 + 1.521)
=-3.091

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Evaxion AS for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.052/( ( (3.322 + max(-3.091, 0)) + (0 + max(0, 0)) )/ 1 )
=-14.052/( ( 3.322 + 0 )/ 1 )
=-14.052/3.322
=-423.00 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -423.00% mean?
Evaxion AS (EVAX) has a ROC (Joel Greenblatt) % of -423.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #673 out of 1321 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Evaxion AS's ROC (Joel Greenblatt) % too high?
Evaxion AS's current ROC (Joel Greenblatt) % is -423.00%. Based on the distribution chart, Evaxion AS ranks #673 out of 1321 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Evaxion AS has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's ROC (Joel Greenblatt) % compare to SER and NRSN?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #673 out of 1321 companies for ROC (Joel Greenblatt) %. This places Evaxion AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Evaxion AS and its competitors. Evaxion AS's current ROC (Joel Greenblatt) % is -423.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current ROC (Joel Greenblatt) % of -423.00%. The current ROC (Joel Greenblatt) % is -423.00%. Evaxion AS's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Evaxion AS (EVAX), the current ROC (Joel Greenblatt) % is -423.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
29GF Score

Get the complete analysis for EVAX

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.43
Price